In 68 patients with extensive-stage small cell lung cancer after chemoimmunotherapy, adding thoracic radiotherapy to atezolizumab maintenance gave no survival benefit (median OS 6.7 vs 13.4 months; HR 1.55, P=.34) and more severe (61.3% vs 18.2%) and fatal adverse events.
RCTn = 68
Bozorgmehr et al. Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320)